Literature DB >> 11232737

Management of type 2 diabetes mellitus in the elderly: special considerations.

J Rosenstock1.   

Abstract

The principles of managing type 2 diabetes mellitus in the elderly are no different from those in younger patients, but the priorities and therapeutic strategies need to be cautiously individualised. The objectives of treatment are to improve glycaemic control in a stepwise approach that involves nonpharmacological methods including diet and exercise, and pharmacological therapy including mixtures of oral antihyperglycaemic agents alone or in combination with insulin. Although the goals of treatment may be the same for elderly and younger patients, certain aspects of type 2 diabetes in the elderly require special consideration. Treatment decisions are influenced by age and life expectancy, comorbid conditions and severity of the vascular complications. Adherence to dietary therapy, physical activity, and medication regimens may be compromised by comorbid conditions and psychosocial limitations. Drug-induced hypoglycaemia has been the main consideration and the most serious potential complication. In addition, the long term macrovascular and microvascular complications of type 2 diabetes are a source of significant morbidity and mortality. Indeed, vascular and neuropathic complications are already present at the time of diagnosis in a significant number of patients, and the impact of improved diabetes control depends on the age and life expectancy of the patient. Age-related changes in pharmacokinetics and the potential for adverse effects and drug interactions should also be considered when choosing appropriate pharmacological therapy. In general, a conservative and stepwise approach to the treatment of the elderly patient with type 2 diabetes is suggested; treatment may be initiated with monotherapy, followed by early intervention with a combination of oral agents including a sulphonylurea as a foundation insulin secretagogue in addition to a supplemental insulin sensitiser. Insulin therapy is eventually required if significant hyperglycaemia [glycosylated haemoglobin (HbA1c) >8%] persists despite oral combination therapy. Combination therapy with evening insulin and a long-acting sulphonylurea such as glimepiride is an effective strategy to improve hyperglycaemia in the elderly patient with type 2 diabetes in whom polypharmacy with oral agents is unsuccessful. In addition, such a regimen is simple to follow for the patient who may not be able to adhere to a more complicated insulin regimen. Hyperglycaemia in the elderly can be managed well with practical intervention and a straightforward treatment plan to enhance compliance. Optimal glycaemic control should be possible for every patient if treatment is individualised; however, strict glycaemic control may not be achievable in all patients or even desirable in many elderly patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11232737     DOI: 10.2165/00002512-200118010-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  36 in total

Review 1.  Thiazolidinediones: a new class of antidiabetic drugs.

Authors:  C Day
Journal:  Diabet Med       Date:  1999-03       Impact factor: 4.359

Review 2.  Evening insulin strategy.

Authors:  M C Riddle
Journal:  Diabetes Care       Date:  1990-06       Impact factor: 19.112

3.  Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  M I Harris; K M Flegal; C C Cowie; M S Eberhardt; D E Goldstein; R R Little; H M Wiedmeyer; D D Byrd-Holt
Journal:  Diabetes Care       Date:  1998-04       Impact factor: 19.112

4.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

5.  UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group.

Authors: 
Journal:  Diabetes Care       Date:  1998-01       Impact factor: 19.112

Review 6.  New treatments for patients with type 2 diabetes mellitus.

Authors:  B H Wolffenbuttel; M B Graal
Journal:  Postgrad Med J       Date:  1996-11       Impact factor: 2.401

7.  A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group.

Authors:  R B Goldberg; S M Holvey; J Schneider
Journal:  Diabetes Care       Date:  1996-08       Impact factor: 19.112

8.  Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group.

Authors:  M C Riddle; J Schneider
Journal:  Diabetes Care       Date:  1998-07       Impact factor: 19.112

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  19 in total

1.  Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial.

Authors:  Paul Hartley; Yue Shentu; Patricia Betz-Schiff; Gregory T Golm; Christine McCrary Sisk; Samuel S Engel; R Ravi Shankar
Journal:  Drugs Aging       Date:  2015-06       Impact factor: 3.923

Review 2.  Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.

Authors:  C R Culy; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Novel drug delivery systems for insulin: clinical potential for use in the elderly.

Authors:  Joël Belmin; Paul Valensi
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

4.  United States patient preference and usability for the new disposable insulin device Solostar versus other disposable pens.

Authors:  Jerome S Fischer; Steven V Edelman; Sherwyn L Schwartz
Journal:  J Diabetes Sci Technol       Date:  2008-11

5.  Hypoglycaemia due to interaction of glimepiride with isoniazid in a patient with type 2 diabetes mellitus.

Authors:  Panagiotis Boglou; Paschalis Steiropoulos; Nikolaos Papanas; Demosthenes Bouros
Journal:  BMJ Case Rep       Date:  2013-04-16

Review 6.  New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.

Authors:  Angela M Abbatecola; Stefania Maggi; Giuseppe Paolisso
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

7.  Effect of glimepiride and nateglinide on serum insulin and glucose concentration in healthy cats.

Authors:  A Mori; P Lee; T Yamashita; Y Nishimaki; H Oda; K Saeki; Y Miki; H Mizutani; K Ishioka; T Honjo; T Arai; T Sako
Journal:  Vet Res Commun       Date:  2009-09-02       Impact factor: 2.459

8.  Efficacy, safety and impact on β-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis.

Authors:  W Gao; Q Wang; S Yu
Journal:  J Endocrinol Invest       Date:  2016-04-12       Impact factor: 4.256

9.  Ayurpharmacoepidemiology Perspective: Health Literacy (Knowledge and Practice) Among Older Diabetes Patients Visiting Ayurveda Teaching Hospitals in India.

Authors:  Parikshit Debnath; Khurshid Natasha; Liaquat Ali; Tapas Bhaduri; Tushar Kanti Roy; Sayantan Bera; Debdeep Mukherjee; Swati Debnath
Journal:  J Evid Based Complementary Altern Med       Date:  2016-07-08

10.  Observational study of once-daily insulin detemir in people with type 2 diabetes aged 75 years or older: a sub-analysis of data from the Study of Once daily LeVEmir (SOLVE).

Authors:  Eddy Karnieli; Florian M M Baeres; Grzegorz Dzida; Qiuhe Ji; Robert Ligthelm; Stuart Ross; Anne Louise Svendsen; Jean-François Yale
Journal:  Drugs Aging       Date:  2013-03       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.